Stock 4507 SHIONOGI & CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
7,306 JPY +2.21% Intraday chart for Shionogi & Co., Ltd. +2.70% +7.47%
Apr. 19 Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares MT
Apr. 18 Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol) CI

Evolution of the average Target Price on Shionogi & Co., Ltd.

Price target over the last 5 years

History of analyst recommendation changes

e03c1504ca086f466a9df06e4e3a18.HedXvW0qlNWjCjVRiO6Fot9M6TwAEabgYPFb4nIDqmg.eIAVywZAobqOU3Ew3pnD8owPoE9zKZS3VpJuoR9x8lx-rWP0WFzBvtVzYA~06acd10dbb8222a99878a788042a1fdf

Analyst Recommendations on Shionogi & Co., Ltd.

Jefferies Adjusts Shionogi’s Price Target to 7,600 Yen From 6,200 Yen, Keeps at Hold MT
Jefferies Adjusts Shinogi & Co’s Price Target to 6,200 Yen From 6,000 Yen, Keeps at Hold MT
Japan Shares Dip as Investors Eye Bank of Japan's Interest Rate Decision Next Week MT
Jefferies Adjusts Shionogi's Price Target to 6,000 Yen From 6,300 Yen, Keeps at Hold MT
Shionogi has been recognized as one of the highest-ranking companies on the Supplier Engagement Rating by CDP AQ
Factbox-US government to impose inflation penalties on 27 drugs RE
Nikkei hits over 2-month high on hopes of Fed slowing rate-hike pace RE
RBC Capital on Bellus Health -- Maintains US$21 PT, Outperform/Speculative Risk Rating MT
GSK Unit ViiV Healthcare's HIV Prevention Drug Shows Lower Rate Of New Infections Among Women In Clinical Trial MT
Nikkei 225 : Off 0.6% On China Outlook, Interest Rates, US Futures MT
Nikkei 225 : Up 0.5%, Extends Rally to Sixth Day on Wall Street Cues, Interest Rates MT
Shionogi : Gains High Rating in Survey by CDP AQ
Shionogi & Co., Ltd. Announces Appearance Rate and Clinical Course of Mutated Viruses at Position 38 in Pa Protein for Influenza A/H1N1pdm and A/H3N2 in Special Drug Use Survey for Xofluza CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
7,306 JPY
Average target price
7,721 JPY
Spread / Average Target
+5.68%
High Price Target
9,000 JPY
Spread / Highest target
+23.19%
Low Price Target
5,500 JPY
Spread / Lowest Target
-24.72%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Shionogi & Co., Ltd.

Jefferies & Co.

Ratings for Shionogi & Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 4507 Stock
  4. Consensus Shionogi & Co., Ltd.